Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24118081 | 0.83 | MAPT (0.51) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL24118611 | 0.81 | CA1 (0.44) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL23593404 | 0.81 | CA1 (0.44) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL23592440 | 0.81 | CA1 (0.44) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL24118254 | 0.80 | FPR2 (0.48) | LMNAMEN1KMT2APOLBHTT | |
| SCHEMBL24118197 | 0.79 | IDO1 (0.55) | MEN1KMT2ASMN1; SMN2HTTKLK7 | |
| SCHEMBL23593322 | 0.77 | POLB (0.48) | MEN1KMT2ASMN1; SMN2POLBHTT | |
| SCHEMBL27815058 | 0.77 | MGLL (0.71) | LMNAMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL24118272 | 0.75 | MEN1 (0.44) | MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL22296876 | 0.74 | LMNA (0.68) | LMNAMEN1KMT2ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393600-A1 | Novel [1.1.1] Bicyclo Compounds as Indoleamine 2,3-Dioxygenase Inhibitors | IDO1, IDO2, TPH1 | LMNA 4578/4885MEN1 1667/4885KMT2A 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.